

BIOLIDICS LIMITED
(Company Registration Number: 200913076M)

COVID-19 ANTIBODY TEST KITS: FURTHER US MARKET UPDATE

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the announcement made on 28 June 2020 in relation to the Company's US market update (the "**Announcement**"). Unless otherwise defined, capitalised terms used herein shall bear the same meanings ascribed to them in the Announcement.

Further to the Announcement, the Board would like to update that on 30 June 2020 (Singapore time), the Company had submitted its application to the US FDA to voluntarily withdraw its application for EUA pursuant to the FDA Serology Test Policy.

In this regard, as of 1 July 2020 (Singapore time), the Company noted from the US FDA website that the COVID-19 Antibody Test Kits are no longer listed in Section IV.D of the Policy for Coronavirus Disease-2019 Tests. As disclosed in the Announcement, without authorisation under the FDA Serology Test Policy, the COVID-19 Antibody Test Kits will no longer be available in the US market.

Shareholders and potential investors should note that policies in relation to diagnosis and/or detection of the COVID-19 virus and/or antibodies in various jurisdictions may change in response to developments in the COVID-19 situation, which is evolving rapidly. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Non-Executive Non-Independent Chairman
2 July 2020

This announcement has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.